Resultados de Búsqueda
For recommendations on assessing sudden-onset unsteady gait in adults, see the NICE guideline on stroke and transient ischaemic attack in over 16s.
NICE
National Institute for Health and Clinical Excellence (NICE)
Refer urgently adults with rapidly (within days to weeks) progressive unsteady gait (gait ataxia) for neurological assessment. Refer adults with gradually progressive unsteady gait (gait ataxia) for neurological assessment. Refer adults who have difficulty initiating and coordinating walking (gait apraxia) to neurology or an elderly care clinic to exclude normal pressure hydrocephalus. For adults with unsteadiness of gait who are at risk of falling, follow the recommendations on ...
ver más ... 2019Durvalumab monotherapy is recommended for use within the Cancer Drugs Fund as an option for treating locally advanced unresectable non-small-cell lung cancer (NSCLC) in adults whose tumours express ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with durvalumab that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Locally advanced NSCLC that is unresectable is usually treated with platinum-based chemoradiation. After this there are no treatment ...
ver más ... 2019Refer urgently adults with facial pain associated with persistent facial numbness or abnormal neurological signs for neuroimaging.
NICE
National Institute for Health and Clinical Excellence (NICE)
Refer adults with unilateral facial pain that is triggered by touching the affected part of the face (trigeminal neuralgia) and is refractory to treatment, in line with the NICE guideline on neuropathic pain in adults. For adults with scalp tenderness or jaw claudication suggestive of temporal arteritis, consider blood tests and follow local pathways for suspected giant cell (temporal) arteritis. Be aware that a normal ESR (erythrocyte sedimentation rate) does not exclude a diagnosis of giant ...
ver más ... 2019Brigatinib is recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC) in adults who have already had ...
NICE
National Institute for Health and Clinical Excellence (NICE)
People with ALK-positive advanced NSCLC that has been treated with crizotinib are currently offered ceritinib as their next treatment. Clinical evidence based on indirect comparisons of trials suggests that people having brigatinib live longer than those having ceritinib, and that they live longer before their condition worsens. Brigatinib may be more effective for brain metastases and better tolerated than existing treatments.
ver más ... 2019Pembrolizumab, with pemetrexed and platinum chemotherapy is recommended for use within the Cancer Drugs Fund, as an option for untreated, metastatic, non-squamous non-small-cell lung cancer (NSCLC) ...
NICE
National Institute for Health and Clinical Excellence (NICE)
It is only recommended if pembrolizumab is stopped at 2 years of uninterrupted treatment or earlier if disease progresses and the company provides pembrolizumab according to the managed access agreement. This recommendation is not intended to affect treatment with pembrolizumab with pemetrexed and platinum chemotherapy that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in ...
ver más ... 2019